USD | FY, 2014 | FY, 2015 | FY, 2016 |
---|---|---|---|
Revenue | 158.9 k | 49.3 k | |
Revenue growth, % | (69%) | (100%) | |
Cost of goods sold | |||
Gross profit | |||
R&D expense | 6.5 m | ||
General and administrative expense | 3.9 m | ||
Operating expense total | 10.4 m | ||
EBIT | (16.6 m) | (14.8 m) | (52.7 m) |
EBIT margin, % | (10452%) | (30063%) | |
Interest expense | 2.2 m | 49.1 k | |
Income tax expense | |||
Net Income | (19.5 m) | (14.1 m) | (43.9 m) |
USD | Q1, 2016 | Q2, 2016 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 |
---|---|---|---|---|---|---|---|
R&D expense | 1.7 m | 2.5 m | 3.9 m | 3.4 m | 3.2 m | 2.1 m | 1.2 m |
General and administrative expense | 1.4 m | 1.2 m | 1.8 m | 1.2 m | 1.3 m | 1.4 m | 1.8 m |
Operating expense total | 3.1 m | 3.7 m | 5.7 m | 4.7 m | 4.5 m | 3.5 m | 3 m |
Interest expense | 1.1 k | 404 | |||||
Net Income | 3 m | 3.5 m | 5.4 m | 4.6 m | 4.3 m | 3.3 m | 3 m |
USD | FY, 2014 | FY, 2015 | FY, 2016 |
---|---|---|---|
Cash | 58.3 m | 7.9 m | 10 m |
Accounts Receivable | 36.4 k | 76.5 k | 72.6 k |
Current Assets | 59 m | 17.5 m | 13.6 m |
PP&E | 124.4 k | 50.3 k | 19.1 k |
Goodwill | 11.3 m | 11.3 m | |
Total Assets | 93.4 m | 82.9 m | 23.3 m |
Accounts Payable | 411.1 k | 1.2 m | 727.6 k |
Current Liabilities | 2.6 m | 4.5 m | 6.2 m |
Long-term debt | 346.9 k | 100.2 k | |
Total Debt | 346.9 k | 100.2 k | |
Total Liabilities | 6.2 m | ||
Additional Paid-in Capital | 219.5 m | 221.1 m | 221.8 m |
Retained Earnings | (136.6 m) | (150.7 m) | (204.7 m) |
Total Equity | 82.9 m | 70.4 m | 17.1 m |
Debt to Equity Ratio | 0 x | 0 x | |
Debt to Assets Ratio | 0 x | 0 x | |
Financial Leverage | 1.1 x | 1.2 x | 1.4 x |
USD | Q1, 2016 | Q2, 2016 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 |
---|---|---|---|---|---|---|---|
Cash | 3.7 m | 5.1 m | 3.3 m | 1.9 m | 722.2 k | 7 m | 2.2 m |
Accounts Receivable | 98.6 k | 86.3 k | 49.3 k | 24.6 k | 72.6 k | 24.6 k | 24.6 k |
Current Assets | 21.6 m | 21.9 m | 16.1 m | 10.2 m | 7.7 m | 12.8 m | 9 m |
PP&E | 54.4 k | 42.1 k | 34 k | 29 k | 23.5 k | 18.3 k | 14.9 k |
Goodwill | 11.3 m | 11.3 m | 11.3 m | 11.3 m | 11.3 m | ||
Total Assets | 78.6 m | 75.5 m | 69.5 m | 64.1 m | 59.7 m | 19.2 m | 13.4 m |
Accounts Payable | 680.7 k | 521.2 k | 2.1 m | 1.5 m | 1.4 m | 1.4 m | 434.2 k |
Current Liabilities | 3.3 m | 3.6 m | 6.2 m | 5.3 m | 5.1 m | 5 m | 2.2 m |
Long-term debt | 48.4 k | ||||||
Total Debt | 48.4 k | ||||||
Total Liabilities | 11.2 m | 11.5 m | 14.2 m | 13.2 m | 13 m | 5 m | 2.2 m |
Additional Paid-in Capital | 221.1 m | 221.2 m | 221.4 m | 221.5 m | 221.7 m | 222.1 m | 222.2 m |
Retained Earnings | (153.7 m) | (157.2 m) | (166.1 m) | (170.7 m) | (175 m) | (207.9 m) | (210.9 m) |
Total Equity | 67.4 m | 63.9 m | 55.3 m | 50.9 m | 46.7 m | 14.1 m | 11.3 m |
Financial Leverage | 1.2 x | 1.2 x | 1.3 x | 1.3 x | 1.3 x | 1.4 x | 1.2 x |
USD | FY, 2014 | FY, 2015 | FY, 2016 |
---|---|---|---|
Net Income | (19.5 m) | (14.1 m) | (10.1 m) |
Depreciation and Amortization | 150.5 k | 148.1 k | 31.2 k |
Inventories | |||
Cash From Operating Activities | (9.3 m) | (9.7 m) | (9 m) |
Purchases of PP&E | (9.8 k) | (4.2 k) | (16.7 k) |
Cash From Investing Activities | (147 k) | (40.9 m) | 4.8 m |
Cash From Financing Activities | 66.9 m | 280.6 k | (100.2 k) |
Interest Paid | 1.5 k |
USD | Q1, 2016 | Q2, 2016 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 |
---|---|---|---|---|---|---|---|
Net Income | (3 m) | (6.6 m) | (5.4 m) | (10 m) | (14.3 m) | (3.3 m) | 6.3 m |
Depreciation and Amortization | 12.7 k | 25 k | 4.6 k | 9.7 k | 14.5 k | 4 k | 7.5 k |
Cash From Operating Activities | (3.8 m) | (6.5 m) | (3.3 m) | (8.5 m) | (12.8 m) | (4 m) | (9.6 m) |
Purchases of PP&E | (16.7 k) | (16.7 k) | (2.9 k) | (2.9 k) | (2.9 k) | (3.3 k) | (3.3 k) |
Cash From Investing Activities | (380.9 k) | 3.8 m | 2.9 m | 6.8 m | 9.8 m | 1.1 m | 1.9 m |
Cash From Financing Activities | (51.8 k) | (100.2 k) | |||||
Interest Paid | 1.1 k | 1.5 k |
USD | Y, 2017 |
---|---|
Financial Leverage | 1.2 x |
FY, 2016 | |
---|---|
Patents Issued | 7 |
Phase III Trials Products | 1 |
Preclinical Phase Products | 1 |